Frontlight ResearchEarly access
Not yet taking people in ItalyPhase 1
Peptide vaccine plus nivolumab for advanced melanoma that stopped responding to immunotherapy
Tests a melanoma vaccine with nivolumab in adults whose melanoma resisted immunotherapy.
Key facts
- Who runs it
- Humanitas Mirasole S.p.A.
- Where
- Milan, Naples, Padova, Perugia, and Rozzano, ItalySee the 5 sites
- Trial code
- Registry title
- A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 25 people, planned
- Started
- 31 Oct 2026
- Expected to end
- 31 Oct 2029
- Type of study
- Interventional
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that has spread or cannot be removed by surgery, and that no longer responds to immune checkpoint blocker treatment. It tests a melanoma peptide vaccine (UniCanVax) together with nivolumab.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic or unresectable stage III/IV melanoma that is refractory to immune checkpoint blockade
- Earlier treatment
- Previous immune checkpoint blocker treatment that no longer works (refractory)
Where in Italy
- Fondazione IRCCS - Istituto Nazionale dei TumoriMilan, ItalyNot yet recruiting
- IRCCS Istituto Nazionale Tumori Fondazione PascaleNaples, ItalyNot yet recruiting
- Istituto Oncologico VenetoPadova, ItalyNot yet recruiting
- Azienda Ospedaliera di PerugiaPerugia, ItalyNot yet recruiting
- Humanitas Mirasole S.p.A.Rozzano, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Peptide vaccine plus nivolumab for advanced melanoma that stopped responding to immunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 November 2026